Medical software developer Densitas has received clearance from the U.S. Food and Drug Administration (FDA) for its machine-learning breast density assessment software, which generates standardized, personalized, automated density reports.
The software is already cleared for clinical use in Australia, Canada, and Europe, according to the firm.
